Yahoo
Swiss - Delayed Quote CHF

Galderma Group AG (GALD.SW)

192.85 +3.15 (+1.66%)
At close: October 30 at 5:30:30 PM GMT+1
Chart Range Bar
Loading chart for GALD.SW
  • Previous Close 189.70
  • Open 190.60
  • Bid --
  • Ask --
  • Day's Range 190.00 - 193.25
  • 52 Week Range 136.30 - 193.90
  • Volume 701,127
  • Avg. Volume 591,473
  • Market Cap (intraday) 44.97B
  • Beta (5Y Monthly) -0.05
  • PE Ratio (TTM) 66.50
  • EPS (TTM) 2.90
  • Earnings Date --
  • Forward Dividend & Yield 0.35 (0.18%)
  • Ex-Dividend Date Apr 24, 2026
  • 1y Target Est 204.48

Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.

www.galderma.com

7,676

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .

YTD Return

GALD.SW
19.23%
MSCI WORLD (^990100-USD-STRD)
9.06%

1-Year Return

GALD.SW
31.75%
MSCI WORLD (^990100-USD-STRD)
9.89%

3-Year Return

GALD.SW
263.87%
MSCI WORLD (^990100-USD-STRD)
0.00%

5-Year Return

GALD.SW
263.87%
MSCI WORLD (^990100-USD-STRD)
53.16%

Earnings Trends

View More

Earnings Per Share (GAAP)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 1.63B
Earnings --
Profit Margin 0.00%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
500M
1B
2B
0.0%

Analyst Insights

View More

Analyst Price Targets

135.23 Low
204.48 Average
192.85 Current
265.39 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    14.57%

  • Return on Assets (ttm)

    5.36%

  • Return on Equity (ttm)

    10.82%

  • Revenue (ttm)

    5.92B

  • Net Income Avi to Common (ttm)

    863M

  • Diluted EPS (ttm)

    2.90

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    839M

  • Total Debt/Equity (mrq)

    33.06%

  • Levered Free Cash Flow (ttm)

    874.63M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: